Reuters: Sanofi-Genzme deal hinges on small price difference

Sanofi-Aventis is seeking to shave an undisclosed amount off its latest Genzyme offer after spending two weeks studying the company's operations, Reuters reports. But is either company prepared to let the deal go for $1 to $2 per share? Report

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.